Joint Panel Favors More Postmarketing Studies For Bayer’s Trasylol
Despite the unanimous recommendation for additional pharmacovigilance for safety, the cardio-renal and drug safety committees vote against taking the product off the market.
Despite the unanimous recommendation for additional pharmacovigilance for safety, the cardio-renal and drug safety committees vote against taking the product off the market.